Exciting mechanism
Novel nasal formulation of relaxin, activating GR and RXFP1 with protective effects.
Treating Multiple Sclerosis
Developing a novel treatment for Multiple Sclerosis.
A hope for the millions of sufferers and their carers.
A FIRST-IN-CLASS TREATMENT FOR MULTIPLE SCLEROSIS
Neuvene™ (Lynflexine™), is a first-in-class drug candidate with disease modifying potential for the treatment of relapsing remitting and progressive forms of multiple sclerosis and for the treatment of neurodegeneration following concussion.
Millions of sufferers
There are now 2.8 million people worldwide who have multiple sclerosis according to the National MS society of the US.
A huge cost to society
The estimated total economic burden of MS just in the US is estimated at $85.4 billion. Neurology May 2022.
A debilitating disease on the rise
The global prevalence of MS has risen since 2013 as published in Insights from the Atlas of MS.
Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and lack of coordination or unsteady gait. MS can occur at any age, but commonly affects people of ages 15–60 years. MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances (Mayo Clinic, 2019).
The diagnosis of MS depends upon the patient symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently, MS is diagnosed by the widely used McDonald criteria, which is a combination of laboratory, clinical, and radiology reports of lesions at different times in different body areas (Lublin, 2014). Currently, there is no cure for MS. However, treatments can help speed recovery from attacks, modify the course of the disease, and manage symptoms (Mayo Clinic, 2019).
A natural hormone
A human hormone, potential as a treatment for MS underpinned by scientific rationale.
First-in-Class
An new and unique mechanism of action to treat multiple sclerosis
Low Risk
Relaxin's targets are known and the molecule is naturally occurring in the body.
Excellent safety
Because the molecule is a human hormone, it is expected to have an excellent safety profile.
Ample evidence
The preclinical results are supported by the known improvement in MS patients during pregnancy.
Neuvene™ (Lynflexine™) - a new treatment for MS
in development targeting Multiple Sclerosis, and other CNS indications. It has the potential to modulate the clinical symptoms of MS, be neuroprotective and promote remyelination.
Our passion, commitment and focus
The potential of Neuvene to remyelinate nerves and restore function creates a paradigm shift in our approach to MS and other neurodegenerative disorders.
Dr Roy Garvin, CEO, BVBiomedical Ltd
Our aim is to meet the challenge of neurodegenerative diseases such as multiple sclerosis and traumatic encephalopathy with transforming nose-to-brain delivery technologies able to unlock the potential of relaxin.
Dr Aikaterini Lalatsa, Reader - Deputy Director CRUK Formulation Unit, School of Pharmacy and Biomedical Science, University of Strathclyde
Re:Cognition Health is excited about the opportunity to work with BVbiomed and their new therapeutic compound “relaxin”, intended for the treatment of neurodegenerative diseases. This new “first in class” medication crosses and stabilises the blood brain barrier and can be delivered as a nasal spray. In the elusive search for an intervention to potentially prevent and treat CTE, this could be a solution and change the future for millions of contact sports players.
Dr J Emer MacSweeney, Co-Founder & CEO Re:Cognition Health
A target product profile which is second to none
Neuvene™ is expected to be a safe and effective treatment in a convenient nasal spray formulation. It is being developed as a therapy for acute attacks in multiple sclerosis; relapsing remitting and chronic forms of multiple sclerosis; neurodegeneration caused by concussion and/or traumatic brain injury.
Learn more
BVBiomed is a research driven company dedicated to the discovery of novel therapeutic compounds for use in treating neuro-degenerative diseases. We are currently developing two new compounds which are anti-inflammatory and auto-immune regulators and are preparing clinical trials of these therapies in treating multiple sclerosis.
Contacts
-
- Address
- Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
-
- Phone
-
- +44 1865 784 062
-
- info [at] bvbiomed . com
(remove spaces between words)